Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast. * Metastatic disease must be measurable or evaluable * Relapsed or progressed during prior treatment with single-agent NSAI, meeting either of the following criteria: * NSAI given as adjuvant therapy that lasted ≥ 12 months OR * Achieved an objective CR, PR, or SD that that lasted ≥ 6 months after prior 1st-line * Female postmenopausal patients Exclusion Criteria: * Hormone receptor status1. ER -ve and PgR NK2. ER-ve and PgR -ve3. ER NK * Prescribed Tamoxifen for metastatic disease * Rapidly progressive visceral disease * Patients with malignancies within the last 5 years.